// startup autopsy
Aviir
Promised to predict heart disease; couldn't predict its own end
marketfitSlow Death
Years-long decline before final shutdown · Fatal mistake: Aviir invested heavily in developing cardiovascular biomarker diagnostics but failed to crack the reimbursement and clinical adoption barriers needed to create a viable commercial business.
Key Events Timeline
FOUNDING
Aviir founded in the USA to develop advanced cardiovascular biomarker diagnostics aimed at improving heart disease risk stratification.
PRODUCT LAUNCH
Aviir launches its MIRISK cardiovascular diagnostic panel, entering the market with a multi-biomarker blood test for heart disease risk assessment.
FUNDING
Follow-on funding secured as Aviir pushes for commercial expansion, but reimbursement coverage remains limited and physician adoption is slower than projected.
FUNDING
Last funding round at $70.93M total. Commercial traction remains insufficient; the company explores partnerships and potential acquirers as capital nears exhaustion.
SHUTDOWN
Aviir ceases operations after failing to achieve commercial viability through sufficient payer reimbursement or physician adoption of its cardiovascular diagnostic platform.